Cargando…
Prevention and Treatment of Monkeypox
Human monkeypox is a zoonotic orthopoxvirus with presentation similar to smallpox. Monkeypox is transmitted incidentally to humans when they encounter infected animals. Reports have shown that the virus can also be transmitted through direct contact (sexual or skin-to-skin), respiratory droplets, an...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244487/ https://www.ncbi.nlm.nih.gov/pubmed/35763248 http://dx.doi.org/10.1007/s40265-022-01742-y |
_version_ | 1784738532220207104 |
---|---|
author | Rizk, John G. Lippi, Giuseppe Henry, Brandon M. Forthal, Donald N. Rizk, Youssef |
author_facet | Rizk, John G. Lippi, Giuseppe Henry, Brandon M. Forthal, Donald N. Rizk, Youssef |
author_sort | Rizk, John G. |
collection | PubMed |
description | Human monkeypox is a zoonotic orthopoxvirus with presentation similar to smallpox. Monkeypox is transmitted incidentally to humans when they encounter infected animals. Reports have shown that the virus can also be transmitted through direct contact (sexual or skin-to-skin), respiratory droplets, and via fomites such as towels and bedding. Multiple medical countermeasures are stockpiled for orthopoxviruses such as monkeypox. Two vaccines are currently available, JYNNEOS(TM) (live, replication incompetent vaccinia virus) and ACAM2000(®) (live, replication competent vaccinia virus). While most cases of monkeypox will have mild and self-limited disease, with supportive care being typically sufficient, antivirals (e.g. tecovirimat, brincidofovir, cidofovir) and vaccinia immune globulin intravenous (VIGIV) are available as treatments. Antivirals can be considered in severe disease, immunocompromised patients, pediatrics, pregnant and breastfeeding women, complicated lesions, and when lesions appear near the mouth, eyes, and genitals. The purpose of this short review is to describe each of these countermeasures. |
format | Online Article Text |
id | pubmed-9244487 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-92444872022-06-30 Prevention and Treatment of Monkeypox Rizk, John G. Lippi, Giuseppe Henry, Brandon M. Forthal, Donald N. Rizk, Youssef Drugs Current Opinion Human monkeypox is a zoonotic orthopoxvirus with presentation similar to smallpox. Monkeypox is transmitted incidentally to humans when they encounter infected animals. Reports have shown that the virus can also be transmitted through direct contact (sexual or skin-to-skin), respiratory droplets, and via fomites such as towels and bedding. Multiple medical countermeasures are stockpiled for orthopoxviruses such as monkeypox. Two vaccines are currently available, JYNNEOS(TM) (live, replication incompetent vaccinia virus) and ACAM2000(®) (live, replication competent vaccinia virus). While most cases of monkeypox will have mild and self-limited disease, with supportive care being typically sufficient, antivirals (e.g. tecovirimat, brincidofovir, cidofovir) and vaccinia immune globulin intravenous (VIGIV) are available as treatments. Antivirals can be considered in severe disease, immunocompromised patients, pediatrics, pregnant and breastfeeding women, complicated lesions, and when lesions appear near the mouth, eyes, and genitals. The purpose of this short review is to describe each of these countermeasures. Springer International Publishing 2022-06-28 2022 /pmc/articles/PMC9244487/ /pubmed/35763248 http://dx.doi.org/10.1007/s40265-022-01742-y Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Current Opinion Rizk, John G. Lippi, Giuseppe Henry, Brandon M. Forthal, Donald N. Rizk, Youssef Prevention and Treatment of Monkeypox |
title | Prevention and Treatment of Monkeypox |
title_full | Prevention and Treatment of Monkeypox |
title_fullStr | Prevention and Treatment of Monkeypox |
title_full_unstemmed | Prevention and Treatment of Monkeypox |
title_short | Prevention and Treatment of Monkeypox |
title_sort | prevention and treatment of monkeypox |
topic | Current Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244487/ https://www.ncbi.nlm.nih.gov/pubmed/35763248 http://dx.doi.org/10.1007/s40265-022-01742-y |
work_keys_str_mv | AT rizkjohng preventionandtreatmentofmonkeypox AT lippigiuseppe preventionandtreatmentofmonkeypox AT henrybrandonm preventionandtreatmentofmonkeypox AT forthaldonaldn preventionandtreatmentofmonkeypox AT rizkyoussef preventionandtreatmentofmonkeypox |